Objective: The purpose of the study was to investigate the association between macrophage migration inhibitory factor (MIF) gene polymorphisms and gestational diabetes mellitus (GDM) in Han Chinese women. Methods: In this study, 915 unrelated pregnant women were recruited, among whom 430 had GDM and 485 served as controls. The rs755622 in the MIF gene (MIF-173G/C) was detected by the polymerase chain reaction Tm-shift genotyping method with fluorescence melting curve analysis. The associations of rs755622 in MIF variants with plasma glucose and insulin levels in the oral glucose tolerance test (OGTT) as well as with with blood fat levels were investigated. Results: The frequencies of genotypes and allele types of rs755622 in MIF were significantly different between women of the GDM and control groups (all p < 0.001). Moreover, the single nucleotide polymorphism (SNP) was significantly associated with increased glucose levels at 0, 60 and 120 min during the OGTT (all p < 0.0038) and with the increased homeostasis model assessment of insulin resistance (p < 0.001) in the GDM group. Conclusion: Genetic polymorphism of rs755622 in MIF is associated with increased risk of GDM and insulin resistance in Han Chinese women.

Keywords:
Macrophage migration inhibitory factor, Polymorphism, Gestational diabetes mellitus
1.
Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N: Comment on: American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl. 1):S11-S61. Diabetes Care 2011;34:e53.
2.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva AD, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI: International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-682.
3.
Kaaja R, Rönnemaa T: Gestational diabetes: pathogenesis and consequences to mother and offspring. Rev Diabet Stud 2008;5:194-202.
4.
Correa PJ, Vargas JF, Sen S, Illanes SE: Prediction of gestational diabetes early in pregnancy: targeting the long-term complications. Gynecol Obstet Invest 2014;77:145-149.
5.
Stuebe AM, Wise A, Nguyen T, Herring A, North KE, Siega-Riz AM: Maternal genotype and gestational diabetes. Am J Perinatol 2014;31:69-76.
6.
Huopio H, Cederberg H, Vangipurapu J, Hakkarainen H, Pääkkönen M, Kuulasmaa T, Heinonen S, Laakso M: Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes. Eur J Endocrinol 2013;169:291-297.
7.
Li C, Qiao B, Zhan Y, Peng W, Chen ZJ, Sun L, Zhang J, Zhao L, Gao Q: Association between genetic variations in MTNR1A and MTNR1B genes and gestational diabetes mellitus in Han Chinese women. Gynecol Obstet Invest 2013;76:221-227.
8.
Bellamy L, Casas JP, Hingorani AD, Williams D: Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373:1773-1779.
9.
Williams MA, Qiu C, Dempsey JC, Luthy DA: Familial aggregation of type 2 diabetes and chronic hypertension in women with gestational diabetes mellitus. J Reprod Med 2003;48:955-962.
10.
Enquobahrie DA, Williams MA, Qiu C, Meller M, Sorensen TK: Global placental gene expression in gestational diabetes mellitus. Am J Obstet Gynecol 2009;200:206.e1-213.
11.
Özyer Ş, Engin-Üstün Y, Uzunlar Ö, Katar C, Danışman N: Inflammation and glycemic tolerance status in pregnancy: the role of maternal adiposity. Gynecol Obstet Invest 2014;78:53-58.
12.
Bloom BR, Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153:80-82.
13.
Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895-1902.
14.
Finucane OM, Reynolds CM, McGillicuddy FC, Roche HM: Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. Proc Nutr Soc 2012;71:622-633.
15.
Stojanovic I, Saksida T, Stosic-Grujicic S: Beta cell function: the role of macrophage migration inhibitory factor. Immunol Res 2012;52:81-88.
16.
Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, Rathmann W, Holle R, Thorand B, Wichmann HE: Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006;29:368-371.
17.
Yilmaz Ö, Küçük M, Kebapçilar L, Altindag T, Yüksel A, Yuvanç HO, Dal T, Savran Y: Macrophage migration-inhibitory factor is elevated in pregnant women with gestational diabetes mellitus. Gynecol Endocrinol 2012;28:76-79.
18.
Ziino O, D'Urbano LE, De Benedetti F, Conter V, Barisone E, De Rossi G, Basso G, Aricò M: The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Leukemia 2005;19:2346-2347.
19.
Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE, Thomson W, Ray D; British Paediatric Rheumatology Study Group: Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2402-2409.
20.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
21.
Papp AC, Pinsonneault JK, Cooke G, Sadée W: Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques 2003;34:1068-1072.
22.
Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Männel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-170.
23.
Kleemann R, Bucala R: Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010;2010:610479.
24.
Makino A, Nakamura T, Hirano M, Kitta Y, Sano K, Kobayashi T, Fujioka D, Saito Y, Watanabe K, Watanabe Y, Kawabata K, Obata JE, Kugiyama K: High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 2010;213:573-578.
25.
Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, van Erk M, de Vries-van der Weij J, Leng L, van Bockel JH, van Dijk KW, Fingerle-Rowson G, Bucala R, Kleemann R: MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 2009;105:99-107.
26.
Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, Leal E, Juárez I, Whitacre C, Kithcart A, Pruitt J, Sielecki T, Satoskar AR, Rodriguez-Sosa M: Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J 2010;24:2583-2590.
27.
Herder C, Klopp N, Baumert J, Müller M, Khuseyinova N, Meisinger C, Martin S, Illig T, Koenig W, Thorand B: Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Diabetologia 2008;51:276-284.
28.
Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C Lueiro M, Ollier WE, Gonzalez-Gay MA: Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002;29:1671-1673.
29.
Mizue Y, Nishihira J, Miyazaki T, Fujiwara S, Chida M, Nakamura K, Kikuchi K, Mukai M: Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med 2000;5:397-403.
30.
Coban N, Onat A Yildirim O, Can G, Erginel-Unaltuna N: Oxidative stress-mediated (sex-specific) loss of protection against type-2 diabetes by macrophage migration inhibitory factor (MIF)-173G/C polymorphism. Clin Chim Acta 2015;438:1-6.
31.
Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL: Correlation of rheumatoid arthritis severity with the genetic functional polymorphisms and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005;52:3020-3029.
32.
Waeber G, Calandra T, Roduit R, Haefliger JA, Bonny C, Thompson N, Thorens B, Temler E, Meinhardt A, Bacher M, Metz CN, Nicod P, Bucala R: Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1997;94:4782-4787.
33.
Plaisance V, Thompson N, Niederhauser G, Haefliger JA, Nicod P, Waeber G, Abderrahmani A: The mif gene is transcriptionally regulated by glucose in insulin-secreting cells. Biochem Biophys Res Commun 2002;295:174-181.
34.
Sakaue S, Nishihira J, Hirokawa J, Yoshimura H, Honda T, Aoki K, Tagami S, Kawakami Y: Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol Med 1999;5:361-371.
35.
Waeber G, Calandra T, Bonny C, Bucala R: A role for the endocrine and pro-inflammatory mediator MIF in the control of insulin secretion during stress. Diabetes Metab Res Rev 1999;15:47-54.
36.
Atsumi T, Cho Y, Leng L, McDonald C, Yu T, Danton C, Hong EG, Mitchell RA, Metz C, Niwa H, Takeuchi J, Onodera S, Umino T, Yoshioka N, Koike T, Kim JK, Bucala R: The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 2007;179:5399-5406.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.